Trial Profile
A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms T2NOW
- Sponsors AstraZeneca; AstraZeneca AB
- 20 Mar 2024 Status changed from active, no longer recruiting to completed.
- 15 Dec 2023 This trial has been completed in Poland.
- 06 Oct 2023 Results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes